← All trials
NCT03511170
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2018
- Primary completion
- Dec 1, 2019
- Completion date
- Jun 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 66
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Harbin Medical UniversityLead sponsor
- Dalian Medical UniversityCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Harbin Medical UniversityCollaborator
- Jilin UniversityCollaborator
- Harbin Medical UniversityReponsible party - principal investigator
- Fudan UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Jilin Provincial Tumor HospitalCollaborator
- Shengjing HospitalCollaborator
- The First People's Hospital of JingzhouCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.